1 completed, 1 recruiting. 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Rivastigmine Transdermal System: new trials by email Literature Review of Rivastigmine Transdermal System trials Research Report on Rivastigmine Transdermal System
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Toward a Computationally-Informed, Personalized Treatment for Hallucinations Rivastigmine Transdermal System, Scopolamine, Placebo Patch - Hallucinations, Auditory, Psychosis | Early Phase 1 | Recruiting | Yale University | 35 | 2021-07-15 | 2025-06-05 |
| CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease) Rivastigmine Transdermal System, Placebo Transdermal System - Parkinson Disease | Phase 3 | Completed | University of Bristol | 600 | 2020-01-02 | 2025-09-29 |
Hallucinations (1) · Parkinson Disease (1) · Psychotic Disorders (1)
University of Bristol (1) · Yale University (1)
United Kingdom (1) · United States (1)
Albert Powers, MD, PhD (1) · Emily Henderson, PhD (1)
R21MH122940 (1)